|
|
|
| Research progress of MTHFR C677T polymorphism and plasma homocysteine level with coronary heart diseases patients with heart failure |
| ZHANG Jianwu1 CHEN Liang2 |
1.Department of Internal Medicine, Weifang Maternal and Child Health Care Hospital, Shandong Province, Weifang 261011, China;
2.Heath Center, Weifang Integrated Chinese and Western Medicine Hospital, Shandong Province, Weifang 261041, China |
|
|
|
Abstract There are many kinds of mutation sites in methylenetetrahydrofolate reductase (MTHFR) gene, among which, C677T is the most common one. MTHFR gene mutation causes the decrease of enzyme activity and heat resistance, causes hyperhomocysteinemia. Homocysteine (Hcy) is an independent risk factor for coronary heart diseases. The average level of Hcy is higher in patients with heart failure. Hcy level increases gradually as the cardiac function deteriorates. This paper reviews the research progress of MTHFR C677T polymorphism and plasma Hcy level with coronary heart diseases patients with heart failure.
|
|
|
|
|
|
[1] Fournier P，Fourcade J，Roncalli J，et al. Homocysteine in Chronic Heart Failure [J]. Clin Lab，2015，61（9）：1137-1145.
[2] Strauss E，Supinski W，Radziemski A，et al. Is hyperhomocysteinemia a causal factor for heart failure The impact of the functional variants of MTHFR and PON1 on ischemic and non-ischemic etiology [J]. Int J Cardiol，2017，228：37-44.
[3] 殷红.血浆Hcy在心力衰竭中的临床价值[J].中国实用医药，2016，11（1）：87-88.
[4] Goyette P，Sumner JS，Milos R，et al. Human methylenetetrahydrofolate reductase：isolation of cDNA，mapping and mutation identification [J]. Nat Genet，1994，7（2）：551.
[5] Frosst P，Blom HJ，Milos R，et al. A candidate genetic risk factor for vascular disease：a common mutation in methylen-etetrahydrofolate reductase [J]. Nat Genet，1995，10（1）：111-113.
[6] 诸军权，肖于飞，秦光明.健康人群中血压增高伴Hcy增高的流行病学调查[J].放射免疫学杂志，2013，26（2）：216-217.
[7] 温少磊，陈晓琳，陈瑶.高血压患者中hcy增高在不同年龄段及性别的构成比调查[J].中国医药指南，2013，11（20）：46.
[8] Lin X，Zhang W，Lu Q，et al. Effect of MTHFR Gene Polymorphism Impact on Atherosclerosis via Genome-Wide Methylation [J]. Med Sci Monit，2016，22：341-345.
[9] 陈梅玲，林小慧，李清华，等.动脉粥样硬化性脑梗死患者血浆同型半胱氨酸水平及亚甲基四氢叶酸还原酶基因多态性[J].中国动脉硬化杂志，2010，18（9）：733-736.
[10] 尹春琳，郭丽娟，谭静，等.急性冠状动脉综合征患者同型半胱氨酸和炎性标记物与基因多态性及肾功能的相关分析[J].中华老年心脑血管病杂志，2013，15（8）：813-816.
[11] 张雄信，徐力辛，章顺荣.MTHFR基因多态性与冠心病关系的Meta分析[J].浙江预防医学，2007，19（2）：4-6，9.
[12] Li YY. Methylenetetrahydrofolate reductase C677T gene polymorphism and coronary artery disease in a Chinese Han population：a meta-analysis [J]. Metabolism，2012，61（6）：846-852.
[13] 蒋健刚，刘俊，陈金国.内皮型一氧化氮合酶和N5，N10-亚甲基四氢叶酸还原酶基因多态性与苏皖地区汉族人群早发冠心病易感性的相关关系[J].中国动脉硬化杂志，2012，20（5）：463-468.
[14] Sarecka-Hujar B，Zak I，Krauze J. The TT genotype of the MTHFR 677C ＞ T polymorphism increases susceptibility to premature coronary artery disease in interaction with some of the traditional risk factors [J]. Acta Medica（Hradec Králové），2012，55（4）：172-179.
[15] Hou X，Chen X，Shi J. Genetic polymorphism of MTHFR C677T and premature coronary artery disease susceptibility：A meta-analysis [J]. Gene，2015，565（1）：39-44.
[16] McCully KS. Vascular pathology of homocysteinemia：implications for the pathogenesis of arteriosclerosis [J]. Am J Pathol，1969，56（1）：111-128.
[17] Boushey CJ，Beresford SA，Omenn GS，et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes [J]. JAMA，1995，274（13）：1049-1057.
[18] 刘长梅，徐会圃，王青海.急性冠脉综合征斑块超声显像特征与同型半胱氨酸及亚甲基四氢叶酸还原酶C677T基因多态性的相关性[J].中国老年学杂志，2012，32（24）：5381-5383.
[19] Gupta SK，Kotwal J，Kotwal A，et al. Role of homocysteine & MTHFR C677T gene polymorphism as risk factors for coronary artery disease in young Indians [J]. Indian J Med Res，2012，135（4）：506-512.
[20] 鄢高亮，王栋，乔勇，等.高同型半胱氨酸水平对冠心病严重程度及支架置入治疗预后的影响[J].中华心血管病杂志，2015，43（11）：943-947.
[21] Vasan RS，Beiser A，D'Agostino RB，et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction [J]. JAMA，2003，289（10）：1251-1257.
[22] Veeranna V，Zalawadiya DK，Niraj A，et al. Homocysteine and reclassification of cardiovascular disease risk [J]. J Am Coll Cardiol，2011，58（10）：1025-1033.
[23] 董少英.冠心病心力衰竭患者的血浆同型半胱氨酸水平与QRS波时限的相关性研究[D].郑州：郑州大学，2013.
[24] Liu Y，Tian T，Zhang H，et al. The effect of homocysteine-lowering therapy with folic acid on flow-mediated vasodilation in patients with coronary artery disease：a meta-analysis of randomized controlled trials [J]. Atherosclerosis，2014，235（1）：31-35.
[25] 刘沙沙，田祥，李放，等.叶酸干预伴高同型半胱氨酸血症的冠心病心力衰竭患者的疗效观察[J].中国循环杂志，2016，31（7）：649-653.
[26] Li Y，Huang T，Zheng Y，et al. Folic Acid Supplementation and the Risk of Cardiovascular Diseases：A Meta-Analysis of Randomized Controlled Trials [J]. J Am Heart Assoc，2016，5（8）：e003768. |
|
|
|
